argenx SE
ARGX
View Detailed Chart
877.940USD
-11.550-1.30%
Close 12/12, 16:00（ET）Quotes delayed by 15 min
53.70BMarket Cap
34.64P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.30%
5 Days
-2.58%
1 Month
-1.55%
6 Months
+51.92%
Year to Date
+42.75%
1 Year
+44.59%
View Detailed Chart
TradingKey Stock Score of argenx SE
Currency: USD Updated: 2025-12-12Key Insights
argenx SE's fundamentals are relatively stable, and its growth potential is good.Its valuation is considered fairly valued, ranking 125/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 931.90.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
argenx SE's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
25
analysts
Buy
Current Rating
931.900
Target Price
+3.46%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
argenx SE Highlights
StrengthsRisks
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 433.23% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 34.64, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 32.28M shares, increasing 0.23% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 103.00 shares of this stock.
argenx SE News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
argenx SE Info
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Ticker SymbolARGX
Companyargenx SE
CEOvan Hauwermeiren (Tim)
Websitehttps://www.argenx.com/
FAQs
What is the current price of argenx SE (ARGX)?
The current price of argenx SE (ARGX) is 877.940.
What is the symbol of argenx SE?
The ticker symbol of argenx SE is ARGX.
What is the 52-week high of argenx SE?
The 52-week high of argenx SE is 934.620.
What is the 52-week low of argenx SE?
The 52-week low of argenx SE is 510.055.
What is the market capitalization of argenx SE?
The market capitalization of argenx SE is 53.70B.
What is the net income of argenx SE?
The net income of argenx SE is 833.04M.
Is argenx SE (ARGX) currently rated as Buy, Hold, or Sell?
According to analysts, argenx SE (ARGX) has an overall rating of Buy, with a price target of 931.900.
What is the Earnings Per Share (EPS TTM) of argenx SE (ARGX)?
The Earnings Per Share (EPS TTM) of argenx SE (ARGX) is 25.344.
Related Instruments
+1.83%
+0.76%
-0.31%
-0.51%
+0.15%
+1.33%
+0.11%
-0.23%
-2.28%
+0.23%
-0.37%
+1.37%
+2.40%
-0.23%
-0.16%
-0.73%
-0.74%
0.00%
-3.65%
